GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Estybon® (proposed trade name) | ON-01910 | ON01910.Na
Compound class:
Synthetic organic
Comment: Rigosertib is a dual kinase inhibitor, affecting the phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (PLK1) pathways. Note that the inhibitory action on PLK1 has been disputed [2]. It is a non-ATP-competitive inhibitor, meaning it inhibits substrate binding to the enzyme.
Note that some bioactivity data may be associated with the sodium salt, PubChem CID 23696523. |
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 2-[[2-methoxy-5-[[(E)-2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonylmethyl]phenyl]amino]acetic acid |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 9516 | rigosertib |
Synonyms ![]() |
| Estybon® (proposed trade name) | ON-01910 | ON01910.Na |
Database Links ![]() |
|
| CAS Registry No. | 592542-59-1 |
| ChEMBL Ligand | CHEMBL1241855 |
| GtoPdb PubChem SID | 223366164 |
| PubChem CID | 6918736 |
| RCSB PDB Ligand | 6FS |
| Search Google for chemical match using the InChIKey | OWBFCJROIKNMGD-BQYQJAHWSA-N |
| Search Google for chemicals with the same backbone | OWBFCJROIKNMGD |
| Search PubMed clinical trials | rigosertib |
| Search PubMed titles | rigosertib |
| Search PubMed titles/abstracts | rigosertib |
| UniChem Compound Search for chemical match using the InChIKey | OWBFCJROIKNMGD-BQYQJAHWSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | OWBFCJROIKNMGD-BQYQJAHWSA-N |
| Wikipedia | Rigosertib |